NEUROTRANSMITTER
RESEARCH
NeuroResearch Clinics teaches
American Medical Association (AMA) certified category 1
continuing medical education on the topic of
neurotransmitter treatment and neurotransmitter testing. Each conference is
started with a 15 minute research history. This
home page is a historical overview of neurotransmitter testing and optimization.
Prior to
neurotransmitter testing
research and the NeuroResearch Clinic medical doctors
were directing
a weight loss program. A primary focus
was the type 2
diabetic patients. When type 2 diabetics lose
enough weight they no longer need diabetes drugs or insulin.
Diabetes
effectively goes away and secondary diseases of
diabetes go away. On "The Diseases" link in the
left black colored column for a list of "secondary
diabetes diseases". Problems were
encountered with drugs used to control
appetite under control allowing patients to eat
less food comfortably and lose weight. During
treatment these drugs quit working. Once the
drugs quit working the patient's appetite returned, weight
gain started, then the need for diabetic drugs
returned. Adjusting prescription drug dosing was not effective.
With 78 diabetics in the practice who were no
longer taking diabetes drugs or insulin a search
was started to find a way to keep the weight
loss drugs
working.
The appetite center of the brain is under the
neurotransmitter control of serotonin and
norepinephrine. How do we know
neurotransmitter control is the key to getting
appetite under control? The only
drugs in medicine that control appetite allowing
patients can eat less food comfortably and work
only with the neurotransmitters serotonin and
norepinephrine. With
this knowledge it was reasoned that either the
serotonin and/or norepinephrine had been
depleted (burned out) during weight loss to the
point that these neurotransmitter
levels were so low
that the drugs no longer worked. Patients were started on
the neurotransmitter nutrients tyrosine (dopamine is the
precursors of norepinephrine) and 5-HTP along with the vitamins and
minerals the body needed to build
neurotransmitter levels. Weight loss results were placed in a data
base and analyzed. Initial results were promising,
it took
six month before the optimal nutrient dosing was
determined to keep the drugs working in weight
loss. Once refined nutrients
proved to be very effective method of keeping the drugs working
in weight loss keeping the patient's
appetite under control was a tremendous
tool in the management of diabetics. In 1999 it was realized that other medical
weight loss programs were having problems with drugs that quit working.
December of
1999 a nutrient formulation was invented that
did not require drugs. Group weight loss with the
nutrient formula was as effective as using
nutrients with prescription drugs. The drugs
were removed from the treatment protocols.
Many weight loss patients after 1 to 2 months of treatment
spontaneously reported
neurotransmitter diseases had resolved. In response,
NeuroResearch Clinics expanded its data base and
began collecting data on these other diseases
(some of these diseases are listed on "The
Diseases" link in the left black colored
column). Depression, anxiety, panic attacks,
insomnia, obsessive compulsive disorder,
migraine headaches, PMS, and a host of other
disease were not just getting better with
neurotransmitter optimization with
nutrient, the symptoms would go away completely
as nutrients
were adjusted to the point of getting the
appetite under control.
What happened next is written about in the links
on the right side of this web page article.
Since 1997 the NeuroResearch Clinics research
project has become immersed the realm of
ground breaking neurotransmitter science on many fronts. All this
would not have been possible without the
NeuroResearch Clinics neurotransmitter data base. This medical
data base was started in 1995 and documents
about 1.5 million patient-days of treatment from
over 650 clinics. The data base continues to
grow daily as doctors use the computer program
hooked to the data base for
treatment of neurotransmitter
disease in patients. This is believed to be the largest
privately held medical neurotransmitter research data base in the world.
NEUROTRANSMITTER
|
